

**E-filed**

**Date of Deposit: August 26, 2010**

**Attorney Docket No. 38447-201N01US**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT:	Christof Westenfelder	Confirmation No.:	6531
SERIAL NUMBER:	10/551,317	EXAMINER:	WEHBE, Anne Marie Sabrina
FILING DATE:	August 21, 2006	ART UNIT :	1633
FOR:	STEM-CELL, PRECURSOR CELL, OR TARGET CELL-BASED TREATMENT OF MULTIORGAN FAILURE AND RENAL DYSFUNCTION		

**MAIL STOP AMENDMENT**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached PTO Form SB/08(a) in the above-identified application, copies of which are submitted herewith.

This Supplemental Information Disclosure Statement is being filed after the mailing of a first Office Action but before the mailing of a final action under 37 C.F.R. § 1.113. The fee required under 37 C.F.R. § 1.17(p) is not believed to be due, as each item of information contained in this Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

Each item of information contained in this Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart application (Australian Application No. 2004227342), which was mailed on July 6, 2010 and received by Applicants' U.S. attorneys on July 29, 2010. As such, this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of this Supplemental Information Disclosure Statement.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the

present claims, and sign the enclosed form PTO/SB/08a to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. § 102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. **50-0311**, Reference No. **38447-201N01US**.

Respectfully submitted,

/ Shovon I. Ashraf /  
\_\_\_\_\_  
Ivor R. Elrifi, Reg. No. 39,529  
Sean M. Coughlin, Reg. No. 48,593  
Shovon I. Ashraf, Reg. No. 62,270  
Attorneys/Agent for Applicants  
MINTZ, LEVIN  
Tel: (202) 434-7450  
Fax: (617) 542-2241  
**Customer no.: 30623**

Date: August 26, 2010